PVP Ventures Limited has successfully completed the acquisition of an additional 4,263 equity shares in 7 Med India Private Limited, as disclosed in a regulatory filing under SEBI Listing Regulations Regulation 30. This acquisition represents the second tranche of the transaction, following earlier intimations dated 28th August 2025 and 4th November 2025.

Transaction Details

  • Shares Acquired: 4,263 equity shares
  • Resulting Shareholding: Company's stake increased to 41.23% of the total paid-up share capital of 7 Med India Private Limited
  • Transaction Completion Date: 07th July 2026
  • Consideration Type: Cash consideration
  • Total Projected Outlay: Approximately ₹127 crores for eventual majority shareholding of 50.62%
  • Transaction Structure: Combination of both primary and secondary stake purchase

Target Company Profile

  • Name: 7 Med India Private Limited (7Med India Pvt Ltd)
  • Industry: Healthcare, specifically renal care services
  • Business Description: Among the top five organized players in India's renal care sector, offering comprehensive dialysis services across a pan-India network

Regulatory and Transaction Framework

  • Executed in accordance with Share Purchase Agreement and Shareholders' Agreement
  • Does not qualify as a related party transaction
  • Conducted on an arm's length basis
  • 7 Med India Private Limited became an associate company of PVP Ventures after the first tranche completed on 4th November 2025
  • No promoter/promoter group/group companies have any interest in the acquired entity other than the disclosed shareholding

Strategic Rationale

The acquisition supports PVP Ventures' strategic expansion into the healthcare sector. The company remains committed to completing the balance acquisition to achieve aggregate stake of 50.62% in accordance with the terms of the definitive agreements executed between the parties.

Future Timeline

The balance shareholding acquisition to reach 50.62% stake is expected to be completed in accordance with the terms of the definitive agreements, though no specific timeline is provided in this disclosure.